XEN<sup>®</sup> 63 gel stent to treat a refractory uveitic glaucoma: A case report

Serrar, Yasmine; Rezkallah, Amina; Kodjikian, Laurent; Mathis, Thibaud; Denis, Philippe

doi:10.1177/11206721221109199

Cited by 5 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a good IOP control without hypotensive medications was reported after 12 months. 24 Similarly, in our case, the patient experienced only early self-limiting complications, such as AC clots and tiny vitreous hemorrhage, with slit lamp examination constantly showing a well-formed inferior diffuse bleb through all follow-up visits.…”

Section: Np28supporting

confidence: 67%

Inferior implant of XEN63 Gel stent in a refractory open-angle glaucoma due to silicone oil tamponade: A case report

Savastano

Carlà

Gambini

et al. 2023

European Journal of Ophthalmology

View full text Add to dashboard Cite

Background To discuss the efficacy of an inferior implant of XEN 63 gel stent in a patient with refractory glaucoma after trabeculectomy failure and vitreoretinal surgery with silicone oil tamponade. Case Description We report the case of a 73-year-old man with a history of refractory open glaucoma with trabeculectomy failure. He experienced recurrent retinal detachments with silicone oil tamponade, with uncontrolled intra-ocular pressure (IOP) after silicone oil removal. Due to the presence of oil emulsion in the anterior chamber, the chosen location for XEN 63 implantation was the infero-temporal quadrant. Mild hyphema and vitreous hemorrhage were seen post-operatively, but were self-limiting. At week 1, the intraocular pressure was 8 mmHg with a well-formed bleb seen in anterior segment optical coherence tomography (AS-OCT). At 6 month follow up, the patient maintained a IOP of 12 mmHg without topical hypotensive drugs. Slit lamp examination revealed a widespread, developed bleb with no signs of inflammation. Conclusion In this case of refractory glaucoma in a vitrectomized eye with previous oil tamponade, the inferior placement of the XEN 63 gel stent delivered an adequate intraocular pressure even at 6-months follow up, with a diffuse functional infero-nasal bleb seen with AS-OCT.

show abstract

Section: Np28supporting

confidence: 67%

Inferior implant of XEN63 Gel stent in a refractory open-angle glaucoma due to silicone oil tamponade: A case report

Savastano

Carlà

Gambini

et al. 2023

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…[13][14][15][16] Currently, only one case report and a case series study with a follow-up of 18 months are available which have used the new XEN63 gel stent with a 27G needle. 17,18 To our knowledge, the current study is the first study reporting on the efficacy and safety of the new XEN63 gel stent after two years.…”

Section: Discussionmentioning

confidence: 89%

New XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study

Voykov,

Nasyrov,

Neubauer

et al. 2023

OPTH

View full text Add to dashboard Cite

The XEN gel stent was developed to reduce the risks of filtration surgery by standardizing the outflow of aqueous humor into the subconjunctival space. Recently, a modified version of the XEN63 gel stent was introduced. The goal of this study was to assess its efficacy and safety. Methods: This is a prospective, nonrandomized, observational, consecutive case series study at a single tertiary centre. Patients with open-angle glaucoma with above target intraocular pressure (IOP) despite maximal tolerated medication were included. The primary outcome was a change of median IOP. Secondary outcomes included a change in the number of medications, complete success, needling and complication rates. Success was defined as a lowering of IOP > 20% from baseline and IOP ≤ 14 mmHg. Complete success indicated that the target IOP was reached without medications. Results: Six patients were included. The median IOP decreased from 35.5 mmHg (25.0-40.0 mmHg) at baseline to 11.5 mmHg (4.0-15.0 mmHg, p = 0.03), and median IOP-lowering medication was reduced from 4.0 (3.0-4.0) at baseline to 0 (0-1.0, p = 0.03) after two years. Five patients (83.0%) had a complete success after two years. Two patients (33.0%) required a needling procedure. Three patients (50.0%) required an intervention due to symptomatic hypotony within the first three weeks postoperatively. Hypotony resolved completely or was asymptomatic after three months. Conclusion:Our study demonstrated a statistically significant reduction in both IOP and number of IOP-lowering medications. Complications were well manageable and had no long-term sequelae.

show abstract

“…Serar et al reported the successful use of Xen-63 with a larger lumen in the case of a refractory neovascular glaucoma due to Fuchs heterochromic iridocyclitis and retinal vein occlusion after the failure of an Ahmed tube. After one-year, intraocular pressure was 16 mmHg without any medication and the bleb was well-formed [ 90 ].…”

Section: Minimally Invasive Glaucoma Surgical (Migs) Devices In Uveit...mentioning

confidence: 99%

Update on Diagnosis and Treatment of Uveitic Glaucoma

Halkiadakis,

Konstantopoulou,

Tzimis

et al. 2024

JCM

View full text Add to dashboard Cite

Glaucoma is a common and potentially blinding complication of uveitis. Many mechanisms are involved alone or in combination in the pathogenesis of uveitic glaucoma (UG). In terms of diagnostic evaluation, the effects of inflammatory activity in the retinal nerve fiber layer may be a source of bias in the interpretation of optical coherence tomography measurements. For the successful treatment of UG, the control of intraocular inflammation specific to the cause or anti-inflammatory treatment, combined with IOP management, is mandatory. The early institution of specific treatment improves the prognosis of UG associated with CMV. The young age of UG patients along with increased failure rates of glaucoma surgery in this group of patients warrants a stepwise approach. Conservative and conjunctival sparing surgical approaches should be adopted. Minimally invasive surgical approaches were proved to be effective and are increasingly being used in the management of UG along with the traditionally used techniques of trabeculectomy or tubes. This review aims to summarize the progress that recently occurred in the diagnosis and treatment of UG.

show abstract

XEN^® 63 gel stent to treat a refractory uveitic glaucoma: A case report

Cited by 5 publications

References 17 publications

Inferior implant of XEN63 Gel stent in a refractory open-angle glaucoma due to silicone oil tamponade: A case report

Inferior implant of XEN63 Gel stent in a refractory open-angle glaucoma due to silicone oil tamponade: A case report

New XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study

Update on Diagnosis and Treatment of Uveitic Glaucoma

Contact Info

Product

Resources

About

XEN® 63 gel stent to treat a refractory uveitic glaucoma: A case report

Cited by 5 publications

References 17 publications

Inferior implant of XEN63 Gel stent in a refractory open-angle glaucoma due to silicone oil tamponade: A case report

Inferior implant of XEN63 Gel stent in a refractory open-angle glaucoma due to silicone oil tamponade: A case report

New XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study

Update on Diagnosis and Treatment of Uveitic Glaucoma

Contact Info

Product

Resources

About

XEN^® 63 gel stent to treat a refractory uveitic glaucoma: A case report